Business Context and Reporting Period
Company: NanoViricides, Inc. (NNVC)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: December 31, 2009
Business Stage: Development Stage Company
Operations: The Company is a nano-biopharmaceutical firm focused on discovering and developing anti-viral therapeutics (nanoviricides) for diseases including HIV, Influenza, Herpes, Hepatitis, and Ebola. It holds exclusive perpetual licenses from TheraCour Pharma, Inc. for its core technology. The Company has no commercialized products and has generated no revenue since inception.
Key Financial Metrics
| Metric | Six Months Ended Dec 31, 2009 | Six Months Ended Dec 31, 2008 | Accumulated Deficit (Inception to Dec 31, 2009) |
|---|---|---|---|
| Revenues | $0 | $0 | $0 |
| Net Loss | $(1,656,637) | $(1,375,255) | $(13,652,172) |
| Operating Expenses | $1,658,627 | $1,401,336 | $13,015,159 |
| Cash and Cash Equivalents (Ending) | $4,032,863 | $1,935,742 | N/A |
| Net Cash Used in Operating Activities | $(711,877) | $(1,515,743) | $(10,100,882) |
| Net Cash Provided by Financing Activities | $3,338,790 | $3,227,554 | $15,319,536 |
| Total Current Liabilities | $1,260,989 | N/A | N/A |
| Shares Outstanding (as of Feb 19, 2010) | 131,910,584 | N/A | N/A |
Material Changes vs. Prior Period
- Liquidity Improvement: Cash and cash equivalents increased significantly from $1,689,442 at June 30, 2009, to $4,032,863 at December 31, 2009, driven by net financing proceeds of $3.34 million.
- Increased Operating Loss: Net loss for the six months ended December 31, 2009, was $1.66 million, compared to $1.38 million in the same period in 2008. This increase was primarily due to higher Research and Development expenses ($1.09 million vs. $0.93 million) and General and Administrative expenses ($0.56 million vs. $0.47 million).
- Liabilities: Total current liabilities rose to $1.26 million from $0.52 million at June 30, 2009. A significant portion of this increase is attributed to accounts payable to related parties, which grew to $957,213.
- Capital Structure: The Company raised approximately $3.22 million in September 2009 through the sale of common stock and warrants and the exercise of existing warrants.
Outlook, Risks, and Management Commentary
- Going Concern: The filing includes a "Substantial Doubt Regarding Ability to Continue as a Going Concern" note. While the Company has sufficient cash to operate through December 31, 2010, it requires an additional $3 million to $5 million over the next 24 months to fund capital costs, staffing, and scientific studies necessary for an Investigational New Drug (IND) filing with the FDA.
- Financing Needs: Management is in discussions with potential investors but has no formal arrangements in place for the required additional capital. Failure to secure funding could result in significant delays or curtailment of operations.
- Development Pipeline: The Company is advancing several drug candidates, including FluCide (pan-influenza), HIVCide, and eye drops for viral conjunctivitis. It recently signed a research agreement with UC Berkeley for Dengue virus testing.
- Related Party Transactions: The Company relies heavily on TheraCour Pharma, Inc. (a related party) for technology licensing, manufacturing, and laboratory supplies. TheraCour owns approximately 30% of the Company's stock. The Company also has significant payables to related parties.
- Subsequent Events: In February 2010, the Company approved an Additional License Agreement with TheraCour for Dengue, Ebola/Marburg, and other viruses, paying a fee of 7 million shares of Series A Convertible Preferred Stock.
Investor Verification Checklist
- Cash Runway: Verify if the Company has secured the additional $3M-$5M financing required to sustain operations beyond December 2010.
- Related Party Dependence: Assess the risks associated with the Company's reliance on TheraCour Pharma, Inc. for technology, manufacturing, and funding, given the significant related-party payables ($957k).
- Regulatory Milestones: Monitor progress toward filing an Investigational New Drug (IND) application with the FDA, which is the primary catalyst for future value.
- Dilution Risk: Review the terms of the Series A Convertible Preferred Stock issued in February 2010 and potential future equity offerings needed to fund operations.
- Revenue Timeline: Confirm that the Company remains in the development stage with no near-term revenue generation expected.